Two Men Joined Forces at a Biotech Firm. One Is Being Hailed for His Work to Cure HIV. The Other Is Going to Prison.

Key Points:

• In 2019, Nader Pourhassan, CEO of CytoDyn, promoted leronlimab, a biotech drug aimed at HIV treatment, with optimistic claims about imminent FDA approval; six years later, he was convicted of fraud and insider trading related to misleading investors about the drug's prospects.
• Jonah Sacha, an OHSU scientist and member of CytoDyn's advisory board, continues to support leronlimab's potential despite Pourhassan's legal troubles, maintaining his belief in the drug's efficacy based on his research involving the CCR5 receptor and HIV.
• CytoDyn's history includes financial struggles, aggressive stock issuance, and shifting focus from HIV to other indications like cancer, while regulatory setbacks and federal investigations culminated in Pourhassan's firing and indictment.
• The case highlights ethical concerns about conflicts of interest in biomedical research, as OHSU researchers hold equity in CytoDyn while conducting studies on leronlimab, raising questions about the trustworthiness and objectivity of the science.
• Despite controversies and criticism from animal rights groups and ethics experts, OHSU defends its industry partnerships as standard practice crucial for innovation, though the situation underscores the challenges of maintaining public trust in scientific integrity.